SRZNW

Surrozen, Inc.

A clinical-stage biotech that turns the body's own repair signals into medicines, Surrozen builds antibody drugs that mimic Wnt proteins — the natural molecules that tell tissue to regenerate. Founded in 2015 by Stanford and other scientists, its lead work targets sight-threatening eye diseases like wet age-related macular degeneration. The name blends "surrogate" and "zen": the engineered antibodies act as stand-ins for the body's repair messengers, long considered impossible to turn into drugs.

WARRANTUnderlying: SRZNCUSIP: 86889P117HealthcareUS1 holder

Warrant expiring August 1, 2031

Ownership Activity Financials Filings

SRZNW

SRZNW

Results of Operations and Financial Condition

Submission of Matters to a Vote of Security Holders

Results of Operations and Financial Condition

Results of Operations and Financial Condition

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Results of Operations and Financial Condition

Termination of a Material Definitive Agreement

Entry into a Material Definitive Agreement